Georgia Legalizes Fentanyl Testing Strips as New Law Takes Effect

A new Georgia law took effect this week that removes a significant barrier to overdose prevention across the state. Senate Bill 6, signed by Governor Brian Kemp earlier this year, legalizes the possession and use of fentanyl testing strips—simple paper tools that can detect the presence of the potent synthetic opioid in drugs before they are consumed.

The change represents a shift in Georgia's approach to the ongoing overdose crisis, which has claimed thousands of lives in the state over the past decade. Prior to July 1, possessing fentanyl testing strips could potentially expose individuals to criminal charges under Georgia's drug paraphernalia laws, creating a deterrent for people seeking to protect themselves from the substance driving the majority of overdose deaths nationwide.

What the New Law Changes

Senate Bill 6 explicitly carves out an exception to Georgia's drug paraphernalia statutes for fentanyl testing strips, making it legal for individuals to possess these harm reduction tools without fear of prosecution. The strips work similarly to at-home pregnancy tests—users dissolve a small sample of their substance in water and dip the strip in, with lines appearing to indicate whether fentanyl is present.

The law does not legalize fentanyl itself, nor does it decriminalize other drug-related activities. It specifically targets the testing equipment, recognizing that people who use drugs may take protective steps when given access to information about what they are consuming.

Georgia joins a growing number of states that have moved to legalize or explicitly protect fentanyl testing strip possession in recent years. Indiana enacted similar legislation in 2025, while Rhode Island, New Mexico, and numerous other states have removed legal barriers to these tools through various legislative or administrative actions.

The Context of Georgia's Overdose Crisis

The timing of this legislative change coincides with continued high rates of overdose mortality across Georgia, even as national trends show improvement. The state recorded approximately 2,300 drug overdose deaths in 2024, with synthetic opioids—primarily illicitly manufactured fentanyl—contributing to the overwhelming majority of fatalities.

Fentanyl's potency, estimated at 50 to 100 times stronger than morphine, means that even minute quantities can prove lethal, particularly for individuals without opioid tolerance. The drug's proliferation in the illicit supply has transformed the risk landscape for substance use, as fentanyl is frequently mixed into other drugs without users' knowledge. Counterfeit pills made to resemble prescription medications like oxycodone or Xanax often contain lethal doses of fentanyl, catching unsuspecting consumers in deadly encounters.

Public health researchers have documented that fentanyl testing strips can serve as an important risk-reduction tool when integrated into broader harm reduction strategies. Studies indicate that a substantial portion of individuals who receive positive test results modify their behavior—either by using smaller amounts, ensuring naloxone is present, using with others who can respond to an overdose, or in some cases, choosing not to use the substance at all.

Implementation Questions Remain

While the legal barrier has been removed, questions persist about how widely available fentanyl testing strips will become in Georgia and who will fund their distribution. The new law does not include state funding for purchasing or distributing testing strips, leaving this role to local health departments, harm reduction organizations, and community-based groups.

Georgia's Opioid Crisis Abatement Trust, which manages settlement funds from pharmaceutical litigation, has allocated more than $90 million since 2023 to addiction-related programs. However, the trust's funding priorities have historically emphasized treatment and recovery services over harm reduction supplies. Whether the trust or other state agencies will now invest in making testing strips widely available remains unclear.

The change also comes amid shifting federal policy on harm reduction. The Trump administration eliminated federal funding for fentanyl test strips through SAMHSA earlier this year, directing resources away from the harm reduction organizations that had been distributing millions of tests annually. This federal pullback places greater responsibility on states and local jurisdictions to fund these tools if they wish to make them accessible.

Broader Legislative Package

Senate Bill 6 was part of a broader package of legislation taking effect July 1 that touches multiple aspects of Georgia's response to substance use and public health. Senate Bill 79, enacted simultaneously, increases criminal penalties for fentanyl trafficking—reflecting the dual approach of harm reduction for users alongside intensified enforcement against distribution networks.

Other health-related laws taking effect this month include Senate Bill 220, which expands Georgia's medical cannabis program by removing the previous 5% THC potency cap and adding new qualifying conditions. Senate Bill 195 allows trained pharmacists to dispense certain HIV prevention medications, potentially expanding access to pre-exposure prophylaxis (PrEP) in underserved areas.

The convergence of these policies illustrates Georgia's multifaceted approach to substance use and related health challenges—combining expanded treatment options, harm reduction tools, and law enforcement measures in an attempt to address a crisis that has proven resistant to single-strategy solutions.

What Comes Next

For harm reduction advocates in Georgia, the legalization of fentanyl testing strips represents a victory years in the making, but one they view as a starting point rather than an endpoint. The challenge now shifts to ensuring that the strips are actually accessible to the people who need them most—those using drugs in unsupervised settings where overdose risk is highest.

Distribution models that have proven effective in other jurisdictions include vending machines stocked with testing strips and naloxone, outreach programs that meet people where they use drugs, and partnerships with syringe service programs where such services are legally permitted. Georgia's legal framework for syringe exchanges remains more restrictive than many states, potentially limiting one avenue for getting testing strips into circulation.

The effectiveness of Georgia's policy change will ultimately be measured not by the statute books but by whether overdose deaths involving fentanyl decrease as a result of improved detection and modified behavior. With the law now in effect, the coming months will reveal how quickly and extensively these harm reduction tools reach the communities where they can save lives.

For individuals and families affected by Georgia's overdose crisis, the new law offers a modest but meaningful tool—one that recognizes the reality that some people will use drugs regardless of legal prohibitions, and that keeping them alive through that use is a prerequisite for any future recovery.